Lack of muc1-regulated β-catenin stability results in aberrant expansion of cd11b +gr1 + Myeloid-derived suppressor cells from the bone marrow

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3554-3562

  Poh, Tze Wei ^a   Bradley, Judy M ^a   Mukherjee, Pinku ^a   Gendler, Sandra J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD11B ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MUCIN 1;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ARTICLE; BONE MARROW; BONE MARROW CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL EXPANSION; CELL FRACTIONATION; CELL MATURATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; FEMALE; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; STEM CELL; SUPPRESSOR CELL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD11B; BETA CATENIN; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; DOWN-REGULATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCIN-1; MYELOID CELLS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 65949089852     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3806     Document Type: Article

References (48)

1. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol 2000; 165: 779-85. (Pubitemid 30484744)
2. Bronte V, Serafini P, De Santo C. et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol 2003; 170: 270-8. (Pubitemid 36026149)
3. Pan PY, Wang GX, Yin B. et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-28
4. Serafmi P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression, Semin Cancer Biol. 2006; 16: 53-65. (Pubitemid 43139709)
5. Sinha P, Clements VK, Fulton AM, Ostrand-Kosenberg S, Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-13. (Pubitemid 46815102)
6. Li Q, Ren J, Kufe D, Interaction of human MUC1 and βcatenin is regulated by Lck and ZAP-70 in activated jurkat T cells, Bioehem Biophys Res Commun 2004; 315: 471-6. (Pubitemid 38183130)
7. Mukherjee P, Tinder TL, Basu GD, Gendler SJ. MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells. J. Leukoc Biol. 2005; 77: 90-9. (Pubitemid 40310697)
8. Agrawal B, Krantz MJ, Parker J, Longenecker BM, Expression of MUC1 mucin on activated human T cells-implications for a role of MUC1 in normal immune regulation. Cancer Res 1998; 58: 4079-81. (Pubitemid 28440559)
9. Treon SP, Mollick JA, Urashima M. et al. MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999; 93: 1287-98. (Pubitemid 29076144)
10. Kruger W, Kroger K, Zander AR. MUC1 expression in hemopoietic tissues. J. Hematother Stem Cell Res 2000; 9: 409-10.
11. Rughetti A, Biffoni M, Pierelli L. et al. Regulated expression of MUC1 epithelial antigen in erythropoiesis. Br J. Haematol 2003; 120: 344-52. (Pubitemid 36194188)
12. Fatrai S, Schepers H, Tadema H, Vellenga E, Daenen SM, Schuringa JJ. Mucinl expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. Exp Hematol 2008; 36: 1254-65.
13. Singh PK, Wen Y, Swanson BJ. et al. Platelet-derived growth factor receptor β-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007; 67: 5201-10. (Pubitemid 46997258)
14. Schroeder JA, Adriance MC, Thompson MC, Carne-nisch TD, Gendler SJ. MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003; 22: 1324-32. (Pubitemid 36384593)
15. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D, MUC1 oncoprotein blocks glycogen synthase kinase 3β-mediated phosphorylation and degradation of β-catenin. Cancer Res 2005; 65: 10413-22 (Pubitemid 41743735)
16. Yuan Z, Wong S, Borrelli A, Chung MA, Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Common 2007; 362: 740-6. (Pubitemid 47368156)
17. Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA. Nuclear association of the cytoplasmic tail of MUC1 and β-catenin. J. Biol. Chem 2003; 278; 38029-39. (Pubitemid 37175334)
18. Scheller M, Huelsken J, Rosenbauer F. et al. Hematopoietic stem cell and multilineage defects generated by constitutive β-eatenin activation. Nat. Immunol 2006; 7: 1037-47 (Pubitemid 44420648)
19. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block, Nat Immunol 2006; 7: 1048-56. (Pubitemid 44420649)
20. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-50. (Pubitemid 40558990)
21. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-80. (Pubitemid 44647433)
22. Spicer AP, Rowse GJ, Lidner TK, Gendler Sj, Delayed mammary tumor progression in Mue-1 null mice. J. Biol. Chem 1995; 270: 30093-101. (Pubitemid 26001684)
23. Novak EK, Reddington M, Zhen L. et al. Inherited thrombocytopenia caused by reduced platelet production in mice with the gunmet al. pigment gene mutation. Blood 1995; 85: 1781-9.
24. Michalke M, Cariers A, Schliess F, Haussinger D. Hypoosmolarity influences the activity of transcription factor NF-κB in rat H4IIE hepatoma cells. FEBS Lett. 2000; 465: 64-8. (Pubitemid 30012116)
25. Spicer AP, Parry G, Patton S, Gendler Sj. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glyeosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J. Biol. Chem 1991; 266: 15099-109. (Pubitemid 21907624)
26. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with EGFR and correlates with MAP kinase activation in the mouse mammary gland. J. Biol. Chem 2001; 276: 13057-64.
27. Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation, J. Lipid Res 2004; 45: 438-47. (Pubitemid 38337990)
28. Al Masri A, Gendler SJ. Mucl affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene 2005; 24: 5799-808. (Pubitemid 43080071)
29. McAuley JL, Linden SK, Png CW. et al. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J. Clin. Invest 2007: 117: 2313-24. (Pubitemid 47219576)
30. Lu W, Hisatsune A, Koga T. et al. Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Mucl knockout mice, J. Immunol 2006; 176: 3890-4. (Pubitemid 44264363)
31. Smith DG, Buffet M, Fenwick AE. et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 2001; 11: 635-9. (Pubitemid 32187945)
32. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3 /MUC1 carcinoma-associated antigen with GSK3β and β-catenin. J. Biol. Chem 2001; 276: 6061-4. (Pubitemid 37373456)
33. Li Y, Ren J, Yu Wh W. et al. The epidermal growth factor receptor regulates interaction of the human DF3 /MUC1 carcinoma antigen with c-Src and β-catenin. J. Biol. Chem 2001; 276: 35239-42. (Pubitemid 37373456)
34. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 51: 293-8. (Pubitemid 34743981)
35. Paraiso KH, Ghansah T, Costello A, Engelman RW, Kerr WG. Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J. Immunol 2007; 178: 2893-900. (Pubitemid 46333167)
36. Nefedova Y, Huang M, Kusmartsev S. et al. Hyper-activation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol 2004; 172: 464-74. (Pubitemid 38020502)
37. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol 2008; 181: 4666-75.
38. Cheng P, Corzo CA, Luetteke N. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp Med 2008; 205: 2235-49.
39. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-43. (Pubitemid 39129439)
40. Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells In cancer. Cancer Metastasis Rev 2006; 25: 323-31.
41. Larrivee B, Pollet I, Karsan A. Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J. Immunol 2005; 175: 3015-24. (Pubitemid 41170520)
42. Iwasaki-Arai J, Iwasaki H, Miyamoto T, Watanabe S, Akashi K. Enforced granulocyte/macrophage colony-stimulating factor signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion. J. Exp Med 2003; 197: 1311-22. (Pubitemid 36617778)
43. + T cells. J. Clin. invest 2006; 116: 2777-90. (Pubitemid 44511641)
44. Serafini P, Meckel K, Kelso M. et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp Med 2006; 203: 2691-702.
45. Schroeder JA, Masri AA, Adriance MC. et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739-47. (Pubitemid 39093019)
46. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-β-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV) -Wnt-1 and MMTV-c-Neu transgenic carcinomas. J. Biol. Chem 2002; 277: 22692-8.
47. Tinder TL, Subramani DB, Basu GD. et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J. Immunol 2008; 181: 3116-25.
48. Poehampalli MR, Bitler BG, Schroeder JA. Transforming growth factor α dependent cancer progression is modulated by Mucl. Cancer Res 2007; 67: 6591-8.